Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL590586 in RET-altered advanced solid tumors
CTR20211547Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of a400 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Sep 2021; status: active.
02
Drugs
a400
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on CTR20211547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211547.